Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
Michael S Anderson,1 Anish Nadkarni,1 Leah A Cardwell,1 Hossein Alinia,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, 2Department of Pathology, 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Background: Br...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spotlight-on-brimonidine-topical-gel-033-for-facial-erythema-of-rosace-peer-reviewed-article-PPA |
| _version_ | 1819262187353407488 |
|---|---|
| author | Anderson MS Nadkarni A Cardwell LA Alinia H Feldman SR |
| author_facet | Anderson MS Nadkarni A Cardwell LA Alinia H Feldman SR |
| author_sort | Anderson MS |
| collection | DOAJ |
| description | Michael S Anderson,1 Anish Nadkarni,1 Leah A Cardwell,1 Hossein Alinia,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, 2Department of Pathology, 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Background: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. Objective: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel.Methods: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data.Results: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3–6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness.Limitations: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications.Discussion: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea. Keywords: patient satisfaction, adverse reactions, side effects |
| first_indexed | 2024-12-23T19:53:42Z |
| format | Article |
| id | doaj.art-db0f679c903d411681b066f074ad93e3 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-23T19:53:42Z |
| publishDate | 2017-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-db0f679c903d411681b066f074ad93e32022-12-21T17:33:19ZengDove Medical PressPatient Preference and Adherence1177-889X2017-07-01Volume 111143115033628Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptabilityAnderson MSNadkarni ACardwell LAAlinia HFeldman SRMichael S Anderson,1 Anish Nadkarni,1 Leah A Cardwell,1 Hossein Alinia,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, 2Department of Pathology, 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Background: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. Objective: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel.Methods: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data.Results: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3–6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness.Limitations: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications.Discussion: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea. Keywords: patient satisfaction, adverse reactions, side effects https://www.dovepress.com/spotlight-on-brimonidine-topical-gel-033-for-facial-erythema-of-rosace-peer-reviewed-article-PPAbrimonidinerosaceaefficacypatient satisfactionsafetyadverse reactionsside effectsacceptability |
| spellingShingle | Anderson MS Nadkarni A Cardwell LA Alinia H Feldman SR Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability Patient Preference and Adherence brimonidine rosacea efficacy patient satisfaction safety adverse reactions side effects acceptability |
| title | Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability |
| title_full | Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability |
| title_fullStr | Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability |
| title_full_unstemmed | Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability |
| title_short | Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability |
| title_sort | spotlight on brimonidine topical gel 0 33 for facial erythema of rosacea safety efficacy and patient acceptability |
| topic | brimonidine rosacea efficacy patient satisfaction safety adverse reactions side effects acceptability |
| url | https://www.dovepress.com/spotlight-on-brimonidine-topical-gel-033-for-facial-erythema-of-rosace-peer-reviewed-article-PPA |
| work_keys_str_mv | AT andersonms spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability AT nadkarnia spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability AT cardwellla spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability AT aliniah spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability AT feldmansr spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability |